MA43715A - Anticorps anti-tnf et fragments fonctionnels correspondants - Google Patents
Anticorps anti-tnf et fragments fonctionnels correspondantsInfo
- Publication number
- MA43715A MA43715A MA043715A MA43715A MA43715A MA 43715 A MA43715 A MA 43715A MA 043715 A MA043715 A MA 043715A MA 43715 A MA43715 A MA 43715A MA 43715 A MA43715 A MA 43715A
- Authority
- MA
- Morocco
- Prior art keywords
- functional fragments
- corresponding functional
- tnf antibodies
- tnf
- antibodies
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16160936 | 2016-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43715A true MA43715A (fr) | 2018-11-28 |
Family
ID=55542586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043715A MA43715A (fr) | 2016-03-17 | 2017-03-16 | Anticorps anti-tnf et fragments fonctionnels correspondants |
Country Status (11)
Country | Link |
---|---|
US (1) | US10787508B2 (fr) |
EP (1) | EP3430041B1 (fr) |
JP (1) | JP7049311B2 (fr) |
KR (1) | KR102392746B1 (fr) |
CN (1) | CN108884156B (fr) |
BR (1) | BR112018017276A2 (fr) |
CA (1) | CA3011500A1 (fr) |
EA (1) | EA039323B1 (fr) |
IL (1) | IL261261B2 (fr) |
MA (1) | MA43715A (fr) |
WO (1) | WO2017158079A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA039201B1 (ru) | 2016-03-17 | 2021-12-16 | Нумаб Инновейшн Аг | Антитела к фно и их функциональные фрагменты |
EP3219727B1 (fr) | 2016-03-17 | 2020-12-16 | Tillotts Pharma AG | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci |
DK3219726T3 (da) | 2016-03-17 | 2020-12-07 | Tillotts Pharma Ag | Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf |
WO2020114616A1 (fr) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci |
EP4110819A1 (fr) * | 2020-02-28 | 2023-01-04 | Apexigen, Inc. | Anticorps anti-sirpa et méthodes d'utilisation |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
EP0519596B1 (fr) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | Procédé pour réduire l'immunogénicité des domaines variables d'anticorps |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993011236A1 (fr) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
NO309690B1 (no) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn |
AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (fr) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO1998024893A2 (fr) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ATE384792T1 (de) | 1998-11-18 | 2008-02-15 | Genentech Inc | Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
AU2006255415B2 (en) | 2005-06-07 | 2011-10-06 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
CN102164958A (zh) | 2008-06-25 | 2011-08-24 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
ES2861592T3 (es) | 2008-06-25 | 2021-10-06 | Novartis Ag | Anticuerpos estables y solubles que inhiben el TNF |
JP5579713B2 (ja) | 2008-07-10 | 2014-08-27 | エスバテック − ア ノバルティス カンパニー エルエルシー | 高分子の送達増強のための方法および組成物 |
EP2593476A2 (fr) * | 2010-07-16 | 2013-05-22 | Ablynx N.V. | Molécules de liaison à un antigène à domaine unique modifiées et leurs utilisations |
US9096669B2 (en) * | 2010-09-30 | 2015-08-04 | Chengdu Kanghong Biotechnologies Co., Ltd. | Humanized anti-TNF-α antibody and antigen-binding fragment (Fab) thereof and use of the same |
CN103299422B (zh) * | 2010-12-29 | 2016-11-02 | 3M创新有限公司 | 具有宽带输出和可控颜色的远程荧光粉led装置 |
AU2014301629B2 (en) | 2013-06-26 | 2020-02-06 | Numab Therapeutics AG | Novel antibody frameworks |
US9416197B2 (en) * | 2013-11-01 | 2016-08-16 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease |
WO2015144852A1 (fr) * | 2014-03-26 | 2015-10-01 | Delenex Therapeutics Ag | Éléments de liaison dirigés contre tnf alpha |
EP3219727B1 (fr) | 2016-03-17 | 2020-12-16 | Tillotts Pharma AG | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci |
EA039201B1 (ru) | 2016-03-17 | 2021-12-16 | Нумаб Инновейшн Аг | Антитела к фно и их функциональные фрагменты |
DK3219726T3 (da) | 2016-03-17 | 2020-12-07 | Tillotts Pharma Ag | Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf |
-
2017
- 2017-03-16 CN CN201780012617.7A patent/CN108884156B/zh active Active
- 2017-03-16 JP JP2019500011A patent/JP7049311B2/ja active Active
- 2017-03-16 IL IL261261A patent/IL261261B2/en unknown
- 2017-03-16 US US16/085,570 patent/US10787508B2/en active Active
- 2017-03-16 MA MA043715A patent/MA43715A/fr unknown
- 2017-03-16 KR KR1020187024778A patent/KR102392746B1/ko active IP Right Grant
- 2017-03-16 BR BR112018017276A patent/BR112018017276A2/pt active Search and Examination
- 2017-03-16 EP EP17710745.5A patent/EP3430041B1/fr active Active
- 2017-03-16 EA EA201892094A patent/EA039323B1/ru unknown
- 2017-03-16 CA CA3011500A patent/CA3011500A1/fr active Pending
- 2017-03-16 WO PCT/EP2017/056218 patent/WO2017158079A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP7049311B2 (ja) | 2022-04-06 |
WO2017158079A1 (fr) | 2017-09-21 |
EA039323B1 (ru) | 2022-01-13 |
JP2019512266A (ja) | 2019-05-16 |
US20190153089A1 (en) | 2019-05-23 |
IL261261B2 (en) | 2024-04-01 |
KR102392746B1 (ko) | 2022-04-29 |
EP3430041B1 (fr) | 2023-05-24 |
CA3011500A1 (fr) | 2017-09-21 |
US10787508B2 (en) | 2020-09-29 |
EA201892094A1 (ru) | 2019-02-28 |
EP3430041A1 (fr) | 2019-01-23 |
IL261261A (en) | 2018-10-31 |
IL261261B1 (en) | 2023-12-01 |
CN108884156B (zh) | 2021-10-01 |
KR20180120684A (ko) | 2018-11-06 |
CN108884156A (zh) | 2018-11-23 |
BR112018017276A2 (pt) | 2019-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
MA47694A (fr) | Anticorps anti-tigit | |
MA49034A (fr) | Anticorps anti-lag3 | |
DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA55347A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
DK3458479T3 (da) | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater | |
MA47268A (fr) | Anticorps anti-gpc3 | |
KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
MA43576A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
MA53434A (fr) | Anticorps anti-tigit | |
DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
MA46057A (fr) | Anticorps anti-ctla4 | |
MA52884A (fr) | Anticorps anti-il-11 | |
DK3307274T3 (da) | Anti-cd123-antistoffer og konjugater deraf | |
DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
BR112016021717A2 (pt) | anticorpos anti-egfr e conjugados anticorpo-fármaco | |
MA43738A (fr) | Anticorps anti-tnfalpha et leurs fragments fonctionnels | |
DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
DK3402821T3 (da) | Psma-bindende antistof og anvendelser deraf | |
MA43717A (fr) | Anticorps anti-tnf et fragments fonctionnels de ceux-ci |